Palbociclib in breast cancer neoadjuvant setting
Autops. Case Rep; 11 (), 2021
Cyclin-dependent kinase 4/6 inhibitors represent a major advance in breast cancer treatment, emerging as the standard of care of the initial treatment of hormone receptor-positive and HER2-negative metastatic breast cancer. Their activity in this subset of patients leads to interest in their use in the a...